Amanda Wilson
Amanda Wilson has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Amy Pointon
Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Cambridge, United Kingdom
1 shared publication - Andrew R. Hall
The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London WC1E 6HX, UK
1 shared publication Craig Stovold
Translational Biomarkers & Bioanalysis, Drug Safety & Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, UK
1 shared publication- Gavin Rhys Lloyd
Phenome Centre Birmingham, University of Birmingham, Edgbaston, Birmingham, UK
1 shared publication Glen Hawthorne
Translational Biomarkers & Bioanalysis, Drug Safety & Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, UK
1 shared publicationLouise Coleman
Charles River Laboratories Edinburgh Ltd, Elphinstone Research Centre, Tranent, East Lothian, EH33 2NE, UK
1 shared publication
Latest Publications
- 20 April 2023
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 141, 105386
Impact of repeated micro and macro blood sampling on clinical chemistry and haematology in rats for toxicokinetic studies
- 20 April 2023
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 141, 105386
Impact of repeated micro and macro blood sampling on clinical chemistry and haematology in rats for toxicokinetic studies
- Open Access
- 21 September 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (9) , 644
An Extensive Metabolomics Workflow to Discover Cardiotoxin-Induced Molecular Perturbations in Microtissues
Discovering modes of action and predictive biomarkers of drug-induced structural cardiotoxicity offers the potential to improve cardiac safety assessment of lead compounds and enhance preclinical to clinical translation during drug development. Cardiac microtissues are a promising, physiologically relevant, in vitro model, each composed of ca. 500 cells. While untargeted metabolomics is capable of generating hypotheses on toxicological modes of action and discovering metabolic biomarkers, applying this technology to low-biomass microtissues in suspension is experimentally challenging. Thus, we first evaluated a filtration-based approach for harvesting microtissues and assessed the sensitivity and reproducibility of nanoelectrospray direct infusion mass spectrometry (nESI-DIMS) measurements of intracellular extracts, revealing samples consisting of 28 pooled microtissues, harvested by filtration, are suitable for profiling the intracellular metabolome and lipidome. Subsequently, an extensive workflow combining nESI-DIMS untargeted metabolomics and lipidomics of intracellular extracts with ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS/MS) analysis of spent culture medium, to profile the metabolic footprint and quantify drug exposure concentrations, was implemented. Using the synthetic drug and model cardiotoxin sunitinib, time-resolved metabolic and lipid perturbations in cardiac microtissues were investigated, providing valuable data for generating hypotheses on toxicological modes of action and identifying putative biomarkers such as disruption of purine metabolism and perturbation of polyunsaturated fatty acid levels.
- 21 September 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (9) , 644
Open AccessAn Extensive Metabolomics Workflow to Discover Cardiotoxin-Induced Molecular Perturbations in Microtissues
Discovering modes of action and predictive biomarkers of drug-induced structural cardiotoxicity offers the potential to improve cardiac safety assessment of lead compounds and enhance preclinical to clinical translation during drug development. Cardiac microtissues are a promising, physiologically relevant, in vitro model, each composed of ca. 500 cells. While untargeted metabolomics is capable of generating hypotheses on toxicological modes of action and discovering metabolic biomarkers, applying this technology to low-biomass microtissues in suspension is experimentally challenging. Thus, we first evaluated a filtration-based approach for harvesting microtissues and assessed the sensitivity and reproducibility of nanoelectrospray direct infusion mass spectrometry (nESI-DIMS) measurements of intracellular extracts, revealing samples consisting of 28 pooled microtissues, harvested by filtration, are suitable for profiling the intracellular metabolome and lipidome. Subsequently, an extensive workflow combining nESI-DIMS untargeted metabolomics and lipidomics of intracellular extracts with ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS/MS) analysis of spent culture medium, to profile the metabolic footprint and quantify drug exposure concentrations, was implemented. Using the synthetic drug and model cardiotoxin sunitinib, time-resolved metabolic and lipid perturbations in cardiac microtissues were investigated, providing valuable data for generating hypotheses on toxicological modes of action and identifying putative biomarkers such as disruption of purine metabolism and perturbation of polyunsaturated fatty acid levels.
- 18 April 2019
- Published by Taylor & Francis in Bioanalysis
- Vol. 11 (7) , 595-599
Bioanalysis – But Not as we Knew It: An Astrazeneca Perspective of the Last 10 Years Evolution to Meet a Diversifying Portfolio
- 18 April 2019
- Published by Taylor & Francis in Bioanalysis
- Vol. 11 (7) , 595-599
Bioanalysis – But Not as we Knew It: An Astrazeneca Perspective of the Last 10 Years Evolution to Meet a Diversifying Portfolio